Table 6. Histomorphometric parameters in pamidronate and control groups

Baseline6 Months
a P < 0.032 control change in baseline versus 6 mo.
b P < 0.022, pamidronate versus control at 6 mo.
Pamidronate (n = 6)
    bone volume/tissue volume (%)27.2 ± 11.326.8 ± 11.8
    mineralized bone volume (%)26.0 ± 11.425.8 ± 11.0
    trabecular thickness (plate; μm)120.4 ± 22.6125.6 ± 51.1
    osteoid thickness (μm)7.5 ± 2.28.0 ± 4.3
    osteoblast number/bone length/100 mm167.6 ± 15426.4 ± 44
    osteoclast number/bone length/100 mm71.4 ± 7224.7 ± 8.4
    erosion depth (μm)16.1 ± 9.912.9 ± 9.6
    activation frequency0.049 ± .031
Control (n = 8)
    bone volume/tissue volume (%)28.6 ± 4.525.7 ± 10.1
    mineralized bone volume (%)27.2 ± 4.224.4 ± 9.7
    trabecular thickness (plate, μm)142.7 ± 37.3115.6 ± 24.1a
    osteoid thickness (μm)8.5 ± 1.47.8 ± 1.7
    osteoblast number/bone length/100 mm57.3 ± 80.839.9 ± 56.8
    osteoclast number/bone length/100 mm32.0 ± 278.7 ± 12.4
    erosion depth (μm)22.7 ± 11.915.8 ± 5
    activation frequency0.381 ± .112b